Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222
| Autor: | Robert J. Behrens, Mark D. Sborov, Heidi Mc Kean, Eliot L Friedman Md, Shauna L. Hillman, Kendrith M. Rowland, Gerald G. Gross, Michael W. Cannon, Philip J. Stella, Aminah Jatoi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors Paclitaxel medicine.medical_treatment Article Disease-Free Survival Carboplatin chemistry.chemical_compound Breast cancer Gefitinib Internal medicine Carcinoma Non-Small-Cell Lung Surveys and Questionnaires Antineoplastic Combined Chemotherapy Protocols Medicine Humans Practice Patterns Physicians' Lung cancer Aged Aged 80 and over Chemotherapy business.industry Patient Selection Age Factors Cancer General Medicine medicine.disease Survival Analysis United States Treatment Outcome chemistry Quinazolines Female Non small cell business medicine.drug |
| Popis: | How do oncologists choose therapy for the elderly? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC = 2) + paclitaxel 50 mg/m(2) days 1, 8, 15 (28-day cycle × 4) followed by gefitinib; or (b) gefitinib 250 mg/day. With (a), 12 of 34 were progression-free at 6 months; median time to cancer progression was 3.9 months. With (b), the same occurred in 11 of 28 patients with the latter being 4.9 months. The most common reason for conventional chemotherapy was oncologists' opinion that the cancer was aggressive, and for gefitinib alone, patients' reluctance to receive chemotherapy. Interestingly, age had no influence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|